Prostate cancer orthotopic

products-servicesPharmatest Services Ltd
June 11th 2014

 

Pharmatest’s orthotopic prostate cancer models are suitable for testing the efficacy of drug compounds against primary tumor growth and dissemination. They involve a surgical procedure where prostate cancer cells are inoculated into the ventral prostate through the dorsal lobe, leading to development of a primary tumor to the site of inoculation.

Description

The major advantage of using orthotopic models is replication of the proper tissue microenvironment that is known to affect tumor growth, metastasis and drug resistance.

Pharmatest offers orthotopic prostate cancer models with AR positive, PSA producing cell lines and with an AR negative cell line. Endpoint measurements include serum PSA levels, tumor size and metastasis frequency.

Several additional parameters can be studied immunohistochemically, including angiogenesis, hypoxia, proliferation rate and apoptosis. In the case of the AR negative cell line, metastases to prostate-draining lymph nodes can also be determined by histology.

Resources

Click on prostate cancer orthotopic models for other information.
Click on Pharmatest to contact the company directly.


Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com